Cost Savings as a Result of Bortezomib Vial Sharing in the University Hospital Center „Mother Teresa„ Tirana
Session
Medical, Dental and Pharmaceutical Sciences
Description
The objective of this study was to calculate the cost savings as a result of bortezomib vial sharing in the University Hospital Center “Mother Teresa” Tirana. This study was a retrospective analysis of the use of bortezomib in patients with multiple myeloma, using vial sharing technique to minimize wastage and has been conducted during the period January 1, 2015 to June 30, 2015 before vial sharing and January 1, 2016 to June 30, 2016 after vial sharing. We compared the cost in euro for the treatment with bortezomib. As a result, a reduction of 25.96% was calculated and due to cost savings we administered 62 individualised preparations of bortezomib more during January 1, 2016 to June 30, 2016 for the same budget allocated. The same approach should be adopted for other suitable drugs prepared in the University Hospital Center “Mother Teresa” Tirana.
Keywords:
Bortezomib, cost savings, vial sharing, Albania
Session Chair
Xhevat Pllana
Session Co-Chair
Dafina Gexha Bunjaku
Proceedings Editor
Edmond Hajrizi
ISBN
978-9951-437-69-1
Location
Pristina, Kosovo
Start Date
27-10-2018 1:30 PM
End Date
27-10-2018 3:00 PM
DOI
10.33107/ubt-ic.2018.355
Recommended Citation
Rustemi, Florjana; Malaj, Ledjan; Hoti, Ela; and Balla, Enida, "Cost Savings as a Result of Bortezomib Vial Sharing in the University Hospital Center „Mother Teresa„ Tirana" (2018). UBT International Conference. 355.
https://knowledgecenter.ubt-uni.net/conference/2018/all-events/355
Cost Savings as a Result of Bortezomib Vial Sharing in the University Hospital Center „Mother Teresa„ Tirana
Pristina, Kosovo
The objective of this study was to calculate the cost savings as a result of bortezomib vial sharing in the University Hospital Center “Mother Teresa” Tirana. This study was a retrospective analysis of the use of bortezomib in patients with multiple myeloma, using vial sharing technique to minimize wastage and has been conducted during the period January 1, 2015 to June 30, 2015 before vial sharing and January 1, 2016 to June 30, 2016 after vial sharing. We compared the cost in euro for the treatment with bortezomib. As a result, a reduction of 25.96% was calculated and due to cost savings we administered 62 individualised preparations of bortezomib more during January 1, 2016 to June 30, 2016 for the same budget allocated. The same approach should be adopted for other suitable drugs prepared in the University Hospital Center “Mother Teresa” Tirana.